These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Long-term treatment of Parkinson's disease with L-Dopa and Dopa-decarboxylase inhibitor: therapeutic results and side effects. Battistin L; Meneghetti G; Rigotti S; Saia A Acta Neurol Scand; 1978 Feb; 57(2):186-92. PubMed ID: 347868 [TBL] [Abstract][Full Text] [Related]
8. Mucuna Pruriens Combined with Carbidopa in Parkinson's Disease: A Case Report. Radder DLM; Tiel Groenestege AT; Boers I; Muilwijk EW; Bloem BR J Parkinsons Dis; 2019; 9(2):437-439. PubMed ID: 30856121 [TBL] [Abstract][Full Text] [Related]
9. Contrasting effects of peripheral decarboxylase inhibitors on plasma activity of aromatic-L-amino acid decarboxylase and semicarbazide-sensitive amine oxidase in Parkinson's disease. Boomsma F; van den Meiracker A; Man in 't Veld A; Schalekamp M Life Sci; 1995; 57(19):1753-9. PubMed ID: 7475917 [TBL] [Abstract][Full Text] [Related]
10. Effects of benserazide on L-DOPA-derived extracellular dopamine levels and aromatic L-amino acid decarboxylase activity in the striatum of 6-hydroxydopamine-lesioned rats. Shen H; Kannari K; Yamato H; Arai A; Matsunaga M Tohoku J Exp Med; 2003 Mar; 199(3):149-59. PubMed ID: 12703659 [TBL] [Abstract][Full Text] [Related]
11. Increased neostriatal dopamine activity after intraperitoneal or intranasal administration of L-DOPA: on the role of benserazide pretreatment. Silva MA; Mattern C; Häcker R; Tomaz C; Huston JP; Schwarting RK Synapse; 1997 Dec; 27(4):294-302. PubMed ID: 9372552 [TBL] [Abstract][Full Text] [Related]
12. Protective effects of L-dopa and carbidopa combined treatments on human catecholaminergic cells. Colamartino M; Padua L; Meneghini C; Leone S; Cornetta T; Testa A; Cozzi R DNA Cell Biol; 2012 Nov; 31(11):1572-9. PubMed ID: 23020119 [TBL] [Abstract][Full Text] [Related]
13. In vivo assessment of decarboxylase inhibition or potentiation: urinary dopamine and L-dopa output after L-dopa administration. Johnson RD; Ruthven CR; Goodwin BL; Sandler M J Neural Transm; 1976; 38(3-4):181-91. PubMed ID: 956809 [TBL] [Abstract][Full Text] [Related]
14. The timing of administration, dose dependence and efficacy of dopa decarboxylase inhibitors on the reversal of motor disability produced by L-DOPA in the MPTP-treated common marmoset. Tayarani-Binazir KA; Jackson MJ; Fisher R; Zoubiane G; Rose S; Jenner P Eur J Pharmacol; 2010 Jun; 635(1-3):109-16. PubMed ID: 20303948 [TBL] [Abstract][Full Text] [Related]
15. A Study for Therapeutic Treatment against Parkinson's Disease via Chou's 5-steps Rule. Lan J; Liu Z; Liao C; Merkler DJ; Han Q; Li J Curr Top Med Chem; 2019; 19(25):2318-2333. PubMed ID: 31629395 [TBL] [Abstract][Full Text] [Related]
16. DopAmide: Novel, Water-Soluble, Slow-Release l-dihydroxyphenylalanine (l-DOPA) Precursor Moderates l-DOPA Conversion to Dopamine and Generates a Sustained Level of Dopamine at Dopaminergic Neurons. Atlas D CNS Neurosci Ther; 2016 Jun; 22(6):461-7. PubMed ID: 26861609 [TBL] [Abstract][Full Text] [Related]
17. Inhibition of decarboxylase and levels of dopa and 3-O-methyldopa: a comparative study of benserazide versus carbidopa in rodents and of Madopar standard versus Madopar HBS in volunteers. Da Prada M; Kettler R; Zürcher G; Schaffner R; Haefely WE Eur Neurol; 1987; 27 Suppl 1():9-20. PubMed ID: 3123242 [TBL] [Abstract][Full Text] [Related]